AORT - Artivion, Inc.
NYSE
->
Healthcare
->
Medical Devices
Kennesaw,
United States
Type: Equity
AORT price evolution
AORT
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $77.97 | $78.95 | $76.57 | $74.14 |
| Inventory | $84.12 | $80.8 | $81.72 | $81.98 |
| Total current assets | $287.96 | $284.96 | $276.79 | $280.67 |
| Long term investments | ||||
| Property, plant & equipment | $79.47 | $79.09 | $80.28 | $82.18 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $803.14 | $789.54 | $784.01 | $792.4 |
| Current liabilities | ||||
| Accounts payable | $11.15 | $11.73 | $10.38 | $13.32 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $152.84 | $50.58 | $45.83 | $57.86 |
| Long term debt | $217.46 | $316.5 | $316.27 | $308.94 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $498.4 | $494.48 | $489.02 | $510.62 |
| Shareholders' equity | ||||
| Retained earnings | -$44.78 | -$42.49 | -$40.37 | -$47.91 |
| Other shareholder equity | -$9.53 | -$15.86 | -$13.54 | -$12.01 |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $74.14 | $69.58 | $58.1 | $48.75 |
| Inventory | $81.98 | $74.48 | $76.97 | $73.04 |
| Total current assets | $280.67 | $247.33 | $247.7 | $234.59 |
| Long term investments | ||||
| Property, plant & equipment | $82.18 | $80.53 | $83.23 | $51.65 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $792.4 | $762.8 | $793.05 | $789.4 |
| Current liabilities | ||||
| Accounts payable | $13.32 | $12 | $10.39 | $9.62 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $57.86 | $49.67 | $44.95 | $60.47 |
| Long term debt | $308.94 | $310.14 | $311.87 | $295.77 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $510.62 | $478.47 | $492.32 | $460.69 |
| Shareholders' equity | ||||
| Retained earnings | -$47.91 | -$17.22 | $1.98 | $20.02 |
| Other shareholder equity | -$12.01 | -$21.61 | -$9.89 | $6.74 |
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $95.78 | $98.02 | $97.43 | $93.67 |
| Cost of revenue | ||||
| Gross Profit | $61.01 | $63.32 | $62.95 | $61.09 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $53.22 | $54.82 | $55.03 | $55.42 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $1.02 | -$0.31 | $5.25 | $3.38 |
| Interest expense | -$8.04 | -$7.95 | -$7.45 | -$3.75 |
| Net income | ||||
| Net income | -$2.29 | -$2.12 | $7.52 | -$3.96 |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $354 | $313.79 | $253.23 | |
| Cost of revenue | ||||
| Gross Profit | $229.18 | $202.52 | $167.78 | |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $212.68 | $204.02 | $159.15 | |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $9.1 | $4.21 | -$0.49 | |
| Interest expense | -$22.12 | -$21.18 | -$16.48 | |
| Net income | ||||
| Net income | -$30.57 | -$19.09 | -$16.68 | |
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$16.76 | -$6.12 | -$3.61 | -$0.5 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $2.03 | $0.56 | $0.74 | $0.86 |
| Effect of exchange rate | -$0.13 | $1 | $0.55 | $0.4 |
| Change in cash and equivalents | -$2.77 | -$3.92 | -$7.82 | $19.59 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$0.5 | -$10.71 | $5.66 | -$73.13 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $0.86 | -$1.64 | -$12.22 | $93.61 |
| Effect of exchange rate | $0.4 | $1.85 | $2.2 | -$5.18 |
| Change in cash and equivalents | $19.59 | -$15.66 | -$6.94 | $27.67 |
News
Fundamentals
| Market cap | $1.25B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 41.91M |
| Revenue | $384.90M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$846.00K |
| Revenue Q/Q | 24.65% |
| Revenue Y/Y | N/A |
| P/E ratio | -1.48K |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 3.25 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$0.02 |
|---|---|
| ROA | -0.11% |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.88 |
| Quick ratio | 1.33 |